Amarantus Bioscience Holdings Inc (AMBS)

[JPetroInc]

***** 11 Remaining Milestones for 4Q-14 *****


2b.) LymPro - incl. patients w/ mild AZ, enrollment 68 patient LP-002 exten. (est. 4Q14)
03.) LymPro - JV Partnership Agreement (est. 4Q14)
05.) LymPro - Partner valid. of APP & CLIA cert. (est. 4Q14)

06.) Eltoprazine - 200 patient Ph. 2b trial PD-LID (est. 4Q14)
07.) Eltoprazine - US IND filed & apvd. for PD-LID (est. 4Q14)

08.) MANF - Ophthalmological ear toxicology complete data sets (est. 4Q14)
10.) MANF / GDNF - Renishaw CED Ph. 2B test trial results (est. 4Q14)
12.) MANF OIS - Ocular Ischemic Syndrome - ODD applic. filed (est. 4Q14)
13.) MANF DB-1 Wolframs - Retinal eye data test results (est. 4Q14)
14.) MANF DB-1 Wolframs - ODD potential (est. 4Q14)
15.) MANF - Goods Mfg. Practices (GMP) for 1st in-man studies (est. 4Q14)

25.) NASDAQ up-listing - (est. 4Q14)


***** Note: all above items were abstracted from the 4 following sources: *****

a.) AMBS Chairmans Blog, dated 8/10/14
b.) Crystal Research Co. Report, dated 9/8/14
c.) SEC 8-K Filing, dated 10/10/14
d.) 10/09 PR – Item #2b, rev.